HK) ("Akeso" or the "Company") is pleased to announce the acceptance of its Investigational New Drug (IND) application by the China National Medical Products Administration (NMPA) for AK139, a ...

Work at Exelixis Inc. has led to the development of antibody-drug conjugates (ADCs) comprising antibodies targeting interleukin-13 receptor subunit α2 (IL-13RA2, IL-13R-α2) covalently linked to a ...

HK) ("Akeso" or the "Company") is pleased to announce the acceptance of its Investigational New Drug (IND) application by the China National Medical Products Administration (NMPA) for AK139, a ...

They put this new approach to the test finding an antibody pair for the Simple Plex Ella platform immunoassay for the cytokine IL-10. Assays for biomarkers like IL-10 must be able to precisely ...

Antibodies that interfere with IL-6 function Tocilizumab is a monoclonal antibody directed against the IL-6 receptor that has established benefit in RA both with regards to clinical efficacy and ...

Anti-IL-4Rα monoclonal antibodies are among the best-selling biologics in this field. MG-K10 is an innovative long-acting anti-IL-4Rα humanizedmonoclonal antibody that simultaneously blocks the ...

Oruka Therapeutics, Inc. (NASDAQ:ORKA), a biopharmaceutical company specializing in diagnostic substances with a market ...

share their discovery that a cytokine called interleukin-12 (IL-12) acts like a switch to direct which antibody response B cells will generate. Both B-cell responses are biologically important ...

Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been ...

Despite the failure of an eczema trial in December, Q32 Bio is sticking with bempikibart. But a phase 2-stage complement inhibitor and a number of the biotech’s “valued colleagues” won’t be so lucky.

“Ulcerative colitis remains a challenging condition, but we have seen promising rates of clinical remission from dual inhibition of TNFα and IL-23 using systemically delivered antibodies ...